<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Risk stratification before living donor kidney transplantation in patients with preformed donor-specific antibodies by different crossmatch methods

Loading...
Thumbnail Image

School / College / Institute

Item type:Organizational Unit,
Item type:Organizational Unit,

Program

KU-Authors

Organization Authors

Co-Authors

Ziemann, Malte

Lindemann, Monika

Hallensleben, Michael

Altermann, Wolfgang

Althaus, Karina

Budde, Klemens

Einecke, Gunilla

Eisenberger, Ute

Ender, Andrea

Feldkamp, Thorsten

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background.Preformed donor-specific HLA antibodies (DSA) are a well-known risk factor in kidney transplantation. There is still considerable debate, however, about the optimal risk stratification among patients with preformed DSA. Additionally, data on the prognostic value of different crossmatch assays in DSA-positive patients are scarce. Methods.DSA-positive living kidney transplant recipients were selected from a multicenter study examining 4233 consecutive renal transplants. An additional 7 patients from 2 further centers were included. Flow cytometric crossmatches (FXM), Luminex-based crossmatches, and virtual crossmatches based on C1q- and C3d-binding antibodies (C1qXM and C3dXM) were performed retrospectively using pretransplant sera and lymphocytes isolated from fresh samples. These samples were obtained from 44 donor and recipient pairs from 12 centers. Clinical outcome data and the control group without DSA were compiled from the previous study and were supplemented by data on 10-y death-censored graft survival (10yGS). Results.Between 19% (C3dXM) and 46% (FXM) of crossmatches were positive. Crossmatch-positive patients showed high incidences of antibody-mediated rejection (AMR) within 6 mo (up to 60% in B-cell FXM+ patients). The incidence of AMR in crossmatch-negative patients ranged between 5% (FXM-) and 13% (C1qXM-). 10yGS was significantly impaired in patients with positive T-cell FXM and total FXM compared with both patients without DSA and those with DSA with negative FXM. Conclusions.Especially FXM are useful for risk stratification, as the outcome of DSA-positive, FXM-negative patients is similar to that of DSA-negative patients, whereas FXM-positive patients have both more AMR and decreased 10yGS. Because of their lower sensitivity, the significance of Luminex-based crossmatches, C1qXM, and C3dXM would have to be examined in patients with stronger DSA.

Source

Publisher

Lippincott Williams and Wilkins

Subject

Citation

item.page.haspartof

Source

Transplantation Direct

item.page.ispartofseries

item.page.edition

DOI

10.1097/TXD.0000000000001680

item.page.datauri

item.page.link

Rights

CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY-NC-ND (Attribution-NonCommercial-NoDerivs)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Item type:Goal, Access status: Open Access ,
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.
Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators